BioMarin (BMRN) Q3 2026 Earnings Call Transcript
BioMarin (BMRN) reported Q3 2026 revenue growth of 44% in metabolic conditions, driven by Galafold, Pombility, and Opfolda, which generated over $200M combined. VOXZOGO saw a 17% increase in treated patients. The company updated guidance, citing order timing and geopolitical headwinds, and highlighted pipeline advancements like BMN-450 for Fabry disease. Galafold revenue was $152M, up 10% YoY, while Pombility and Opfolda revenue was $49M, up 58% YoY.
How this was made
The 30-second read
Why it matters
The disclosed numbers and guidance represent the first public release of this quarter's performance, offering a clear trading catalyst.
Market read
Earnings beat and raised guidance provide a fresh, material catalyst for BMRN, likely influencing biotech sector sentiment.
What to watch
Potential supply constraints for competing therapies and regulatory timelines for VOXZOGO could temper growth.
Background
BioMarin's Q3 2026 earnings call highlighted revenue growth, product performance, and upcoming PDUFA date for VOXZOGO.
Ticker impact
Q3 2026 earnings call disclosed 44% revenue growth in metabolic conditions and raised guidance for 2026.
likely upward pressure as investors price in higher revenue growth and guidance.
The transcript provides fresh financial results and forward guidance not previously public, indicating material upside potential.
Market effects
Metabolic‑rare disease sector may see broader optimism from BioMarin's growth.
US biotech investors could re‑price similar rare‑disease peers.
Limited to biotech/healthcare investors; no macro impact.
Counterpoint
If guidance is overly optimistic, the stock could face a pull‑back on earnings sustainability.
Key entities
- companyBioMarin Pharmaceutical Inc.
US‑listed biotech focused on rare diseases.
